Business Context and Reporting Period
This Form 8-K Current Report was filed by Skye Bioscience, Inc. on October 3, 2022, covering events occurring on September 29 and September 30, 2022. The filing primarily addresses a change in the company's independent registered public accounting firm and the results of a Special Meeting of Stockholders held to approve a proposed arrangement with Emerald Health Therapeutics, Inc. (EHT).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on corporate governance and transactional events rather than financial results.
Material Changes
- Change in Certifying Accountant: Effective September 29, 2022, the Audit Committee dismissed Friedman LLP and engaged Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022. This follows Friedman LLP's combination with Marcum LLP on September 1, 2022.
- Stockholder Vote Results: On September 30, 2022, stockholders voted on five proposals. A quorum was established with 368,396,357 shares represented out of 495,925,112 outstanding shares.
Guidance, Outlook, and Management Commentary
The filing details the approval of a critical corporate transaction:
- Arrangement Proposal (Proposal 1): Stockholders approved the Arrangement Agreement with Emerald Health Therapeutics, Inc. This includes the acquisition by Skye of all outstanding EHT shares. Excluding shares held by affiliates and insiders, 162,369,593 votes were cast in favor, while 111,431,876 abstained.
- Other Approved Proposals: Stockholders also approved the 2022 Employee Stock Purchase Plan, the Amended and Restated 2014 Omnibus Incentive Plan, the ratification of the new accounting firm, and an adjournment proposal.
- Accounting Firm Transition: The company confirmed no disagreements or reportable events occurred with the former accountant, Friedman LLP, during the past two fiscal years or the interim period through September 29, 2022.
Investor Verification Checklist
- Verify the terms and closing conditions of the Arrangement Agreement with Emerald Health Therapeutics, Inc. referenced in Proposal 1.
- Review the definitive proxy statement filed on August 31, 2022, for detailed financial and operational implications of the merger.
- Confirm the transition timeline and audit scope between Friedman LLP and Marcum LLP for the 2022 fiscal year.
- Monitor subsequent filings for the official closing of the EHT acquisition and any related capital structure changes.